Changpu Yu

2.0k citations

22 papers · 1.5k indexed · h-index 12

Impact in

Hepatology top 5%
- Liver physiology and pathology
Oncology top 5%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Bone health and treatments

Papers in

Hematology 9
- Multiple Myeloma Research and Treatments 8
- Acute Myeloid Leukemia Research 4
Oncology 11
- CAR-T cell therapy research 6
- Bone health and treatments 2

Co-authors: James C. Geoghegan John Latham David G. Winkler May Kung Sutherland John E. Skonier May S.K. Sutherland George C. Yeoh Jonathan A. Rhim
Journals: Blood (10 papers)Journal of Biological Chemistry (3 papers)mAbs (2 papers)Bone (2 papers)Cancer Research (2 papers)
Partner nations: United States Australia Netherlands

In The Last Decade

Changpu Yu

22 papers receiving 1.4k citations

Peers

Countries citing papers authored by Changpu Yu

Since Specialization

Citations

This map shows the geographic impact of Changpu Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changpu Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changpu Yu more than expected).

Fields of papers citing papers by Changpu Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changpu Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changpu Yu. The network helps show where Changpu Yu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Changpu Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Changpu Yu Line = papers co-authored together Changpu Yu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma Blood ·David R. Taft, Clark M. Henderson, Christine O’Day, Changpu Yu, Juliana C. Radjabycolle, Ir. M. Gerard, Heather Van Epps	2021	2
2	783 SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors SHILAP Revista de lepidopterología ·Byron H. Kwan, Małgorzata Arska-Kotlińska, Shcherbak Em, Changpu Yu, 刘晓越, Mahdi Maleki-Kakelar, Aline de Matos, Jessica K. Simmons, Kelly Hensley, Christina L. Zuch de Zafra, Haley D. Neff‐LaFord, Shawna Hengel, Andres Forero‐Torres, Heather Van Epps	2021	2
3	Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies Blood ·Maureen C. Ryan, Maria Corinna Palanca-Wessels, Brian Schimpf, Kristine A. Gordon, Heather Kostner, 罗翔, Changpu Yu, Heather A. Van Epps, Dennis R. Benjamin	2017	18
4	Denintuzumab Mafodotin Stimulates Immune Responses and Synergizes with CD20 Antibodies to Heighten Anti-Tumor Activity in Preclinical Models of Non-Hodgkin Lymphoma Blood ·Heather A. Van Epps, Ryan A. Heiser, Anthony Cao, Kerry Klussman, Changpu Yu, Ivan J. Stone, Jason Neale, Shyra J. Gardai, Che‐Leung Law, Maureen C. Ryan	2016	2
5	SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies Blood ·Maureen C. Ryan, Brian Schimpf, Martha E. Anderson, Weiping Zeng, Kim K. Emmerton, Jamie B. Miyamoto, Heather Kostner, Changpu Yu, Heather Van Epps, Lori Nerbonne, Dennis R. Benjamin	2015	4
6	SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML Blood ·May S.K. Sutherland, Changpu Yu, Christine O’Day, Wendy Glantz Bogage, Martha E. Anderson, Kim K. Emmerton, Nevena Baljosevic, Megan M. O’Meara, Eric J. Feldman, Dana A. Kennedy, Maureen C. Ryan, Dennis R. Benjamin	2015	8
7	SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML Blood ·May S.K. Sutherland, Changpu Yu, Roland B. Walter, Lori Westendorf, John Valliere‐Douglass, Mirna Lucaccini, Django Sussman, Martha E. Anderson, Weiping Zeng, Ivan J. Stone, Kerry Klussman, Michelle Ulrich, Mechthild Jonas, Peter D. Senter, Jonathan G. Drachman, Dennis R. Benjamin	2015	17
8	SGN-CD33A in Combination with Cytarabine or Hypomethylating Agents Demonstrates Enhanced Anti-Leukemic Activity in Preclinical Models of AML Blood ·May S.K. Sutherland, Changpu Yu, Martha E. Anderson, Kim K. Emmerton, Weiping Zeng, Megan M. O’Meara, Dana A. Kennedy, Maureen C. Ryan, Dennis R. Benjamin	2014	2
9	SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML Blood ·May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey, Patrick Burke, Changpu Yu, Heather Kostner, Ivan J. Stone, Maureen C. Ryan, Django Sussman, Robert P. Lyon, Weiping Zeng, Kimberly H. Harrington, Kerry Klussman, Lori Westendorf, David W. Meyer, Irwin D. Bernstein, Peter D. Senter, Dennis R. Benjamin, Jonathan G. Drachman, Julie A. McEarchern	2013	291
10	SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML Blood ·May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey, Patrick Burke, Changpu Yu, Kimberly H. Harrington, Ivan J. Stone, Maureen C. Ryan, Django Sussman, Weiping Zeng, Dennis R. Benjamin, Irwin D. Bernstein, Peter D. Senter, Jonathan G. Drachman, Julie A. McEarchern	2012	7
11	5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia mAbs ·May Kung Sutherland, Changpu Yu, Martha E. Anderson, Weiping Zeng, Nico van Rooijen, Eric L. Sievers, Iqbal S. Grewal, Che‐Leung Law	2010	24
12	Abstract 4394: Development of parallel conjugation and assay methodologies to screen for antibodies with optimal properties for use as antibody-drug conjugates Cancer Research ·Robert P. Lyon, Maureen C. Ryan, May Kung Sutherland, 罗翔, Changpu Yu, Heather Kostner, Jamie B. Miyamoto, Dennis R. Benjamin	2010	1
13	Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia mAbs ·May Kung Sutherland, Changpu Yu, Timothy S. Lewis, Jamie B. Miyamoto, Md Mahbub Ul Karim Khan, Mechthild Jonas, Jennifer Sutherland, Albina Nesterova, Hans‐Peter Gerber, Eric L. Sievers, Iqbal S. Grewal, Che‐Leung Law	2009	32
14	Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates Journal of Biological Chemistry ·May S.K. Sutherland, Russell J. Sanderson, Kristine A. Gordon, Jamie B. Andreyka, Charles G. Cerveny, Changpu Yu, Timothy S. Lewis, Damon L. Meyer, Roger F. Zabinski, Svetlana O. Doronina, Peter D. Senter, Che‐Leung Law, Alan F. Wahl	2006	222
15	SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages. Blood ·May S.K. Sutherland, Timothy S. Lewis, Changpu Yu, Julie A. McEarchern, Jonathan G. Drachman, Eric L. Sievers, Iqbal S. Grewal, Che‐Leung Law	2006	2
16	Noggin and Sclerostin Bone Morphogenetic Protein Antagonists Form a Mutually Inhibitory Complex Journal of Biological Chemistry ·David G. Winkler, Changpu Yu, James C. Geoghegan, Ethan W. Ojala, John E. Skonier, W. Jurczak, May Kung Sutherland, John Latham	2004	82
17	Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation Bone ·May Kung Sutherland, James C. Geoghegan, Changpu Yu, Eileen Turcott, John E. Skonier, David G. Winkler, John Latham	2004	180
18	Sclerostin Inhibition of Wnt-3a-induced C3H10T1/2 Cell Differentiation Is Indirect and Mediated by Bone Morphogenetic Proteins Journal of Biological Chemistry ·David G. Winkler, May S.K. Sutherland, Ethan W. Ojala, Eileen Turcott, James C. Geoghegan, W. Jurczak, John E. Skonier, Changpu Yu, John Latham	2004	139
19	Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts Bone ·May Kung Sutherland, James C. Geoghegan, Changpu Yu, David G. Winkler, John Latham	2004	69
20	Establishment, Characterization, and Long–Term Maintenance of Cultures of Human Fetal Hepatocytes Hepatology ·Catherine A. Lázaro, Emma Croager, Claudia Mitchell, Jean S. Campbell, Changpu Yu, Jessica Foraker, Jonathan A. Rhim, George C. Yeoh, Nelson Fausto	2003	158

About Changpu Yu

Changpu Yu is a scholar working on Hematology, Oncology, Immunology and Allergy, Hepatology and Radiology, Nuclear Medicine and Imaging, having authored 22 papers that have together received 1.5k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (8 papers), CAR-T cell therapy research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Acute Myeloid Leukemia Research (4 papers), Protein Degradation and Inhibitors (3 papers), Bone Metabolism and Diseases (3 papers), Glycosylation and Glycoproteins Research (2 papers) and Bone health and treatments (2 papers). The work is most often cited by research in Hepatology (222 citations), Oncology (674 citations), Hematology (180 citations), Orthopedics and Sports Medicine (128 citations) and Radiology, Nuclear Medicine and Imaging (279 citations). Changpu Yu has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include James C. Geoghegan, John Latham, David G. Winkler, May Kung Sutherland, John E. Skonier, May S.K. Sutherland, George C. Yeoh, Jonathan A. Rhim, Nelson Fausto and Eileen Turcott. Their work appears in journals such as Blood, Journal of Biological Chemistry, mAbs, Bone and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact